Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its price target dropped by analysts at Morgan Stanley from $14.00 to $7.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage presently has an “underweight” rating on the stock.

Several other research analysts have also recently weighed in on TEVA. Mizuho reiterated a “hold” rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Monday. Jefferies Group LLC reiterated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Deutsche Bank AG cut shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a report on Friday. Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $42.00 to $28.00 in a report on Friday, August 4th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Five analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus price target of $27.21.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, November 2nd. The company reported $1.00 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.03). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.61 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the previous year, the company posted $1.31 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/teva-pharmaceutical-industries-limited-teva-price-target-lowered-to-7-00-at-morgan-stanley.html.

Several institutional investors and hedge funds have recently modified their holdings of TEVA. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at about $106,000. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the period. Penserra Capital Management LLC bought a new position in Teva Pharmaceutical Industries Limited during the third quarter worth about $129,000. Finally, Cutler Capital Management LLC bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. 56.55% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.